Previous close | 0.6500 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 12.50 |
Expiry date | 2024-09-20 |
Day's range | 0.5500 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 40 |
Insight into Avadel Pharmaceuticals' Q1 Financial Performance and Strategic Updates
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 0
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada